Argos Therapeutics, Inc. (Formerly Merix Bioscience)
4233 Technology Drive
Durham
North Carolina
27704
United States
Tel: 919-287-6300
Fax: 919-287-6301
Website: http://www.argostherapeutics.com/
215 articles about Argos Therapeutics, Inc. (Formerly Merix Bioscience)
-
Argos Announces Issuance of Patent Covering the Foundation for Manufacturing Its HIV Immunotherapy
2/15/2018
The methods described in this patent form the foundation for the manufacture of AGS-004, Argos’ novel, dendritic cell-based immunotherapy for HIV.
-
Argos Announces One-for-Twenty Reverse Stock Split
1/18/2018
The Board of Directors approved a one-for-twenty reverse split of the Company’s common stock that will take effect today, January 18, 2018 after the close of trading.
-
Argos Announces $1.5M Equity Investment by Lummy (Hong Kong), Ltd.
1/8/2018
The Company has agreed to file a registration statement with the SEC registering the resale of the shares sold pursuant to the stock purchase agreement.
-
Argos Terminates Lease Agreement
11/28/2017
Argos has entered into a lease termination agreement with TKC pursuant to which Argos received cash proceeds of approximately $1.8 million.
-
Argos Therapeutics Provides Update on Immunology Data from the Phase III ADAPT Trial Presented at the SITC 2017 Annual Meeting
11/13/2017
The presentation is focused primarily upon immunology data from the ADAPT clinical trial and includes both new data and an update to data that was previously presented at the European Society of Medical Oncology Conference in September.
-
Investors in beleaguered Argos are smiling this morning after the company announced some positive interim data for its Phase III kidney cancer drug, Rocapuldencel-T - a trial that some said should have been scrapped months ago.
-
Argos Reports Third Quarter 2017 Financial Results and Operational Highlights
11/10/2017
Revenue for the three months ended September 30, 2017 was $53,000 compared to $147,000 for the same period in 2016.
-
Argos Announces Receipt of Milestone Payment From Lummy (Hong Kong) Co. Ltd.
11/7/2017
The milestone payment was made in consideration of the successful initiation of technology transfer related to the manufacturing of Rocapuldencel-T to Lummy by the Company, to which Lummy has a license for commercialization in these territories.
-
Argos To Hold Conference Call To Discuss Update On The Phase III Adapt Trial Presented At The ESMO 2017 Congress
9/19/2017
-
Argos Reports On Interim Analysis Of Phase III ADAPT Trial Presented At ESMO 2017 Congress
9/12/2017
-
Argos Announces First Dosing Of HIV Patient With AGS-004 Derived From The Latent Viral Reservoir
9/6/2017
-
Argos Announces Interim Analysis Of Phase III ADAPT Trial To Be Presented At ESMO 2017 Congress
8/21/2017
-
Argos Reports Second Quarter 2017 Financial Results And Recent Operational Highlights
8/10/2017
-
Argos Reports Immunogenicity Results Of AGS-004 In HIV Program
7/26/2017
-
Argos Announces Closing Of $6 Million Secured Convertible Note Financing
6/22/2017
-
Argos Announces $6 Million Secured Convertible Note Financing
6/16/2017
-
Argos Provides Update On Its ADAPT Trial Following Meeting With FDA
5/10/2017
-
Argos Reports Interim Results Of The ADAPT Trial And Provides Perspective On Decision To Continue The Trial
4/19/2017
-
Argos Cuts Staff by 38% After Devastating Phase III News
3/10/2017
-
Committee Recommends Discontinuation of Argos' Phase III Renal Cell Carcinoma Study
2/22/2017